Essential genes in thyroid cancers: focus on fascin

Journal of Diabetes & Metabolic Disorders

Vahid Haghpanah²  Bagher Larijani²  Masoud Soleimani¹  Patricia Khashayar²  Abolhasan Shahzadeh fazeli³  Mohsen Ghadami⁴  Majid Zaki dizaji⁴  Hilda Samimi² 

[1] Department of Hematology, Faculty of Medical Science, Tarbiat Modares University, Tehran, Iran;Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Research Institute, Tehran University of Medical Sciences, 5th floor, Dr. Shariati Hospital, North Kargar Ave, Tehran, Iran;Science and Culture University, Tehran, Iran;Department of Medical Genetics, Tehran University of Medical Sciences, Tehran, Iran

关键词: Fascin;    PPARγ;    BRAF;    RET;    RAS;    P53;    Rearrangement;    Mutation;    Thyroid cancer;   

Others  :  806942
DOI  :  10.1186/2251-6581-12-32

 received in 2013-06-23, accepted in 2013-06-25,  发布年份 2013

【 摘 要 】

Although thyroid cancers are not among common malignancies, they rank as the first prevalent endocrine cancers in human. According to the results of published studies it has been shown the gradual progress from normal to the neoplastic cell in the process of tumor formation is the result of sequential genetic events. Among them we may point the mutations and rearrangements occurred in a group of proto-oncogenes, transcription factors and metastasis elements such as P53, RAS,RET,BRAF, PPARγ and Fascin. In the present article,we reviewed the most important essential genes in thyroid cancers, the role of epithelial mesenchymal transition and Fascin has been highlighted in this paper.

【 授权许可】

   
2013 Samimi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Cobin R, Gharib H, Bergman D, Clark O, Cooper D, Daniels G, Dickey R, Duick D, Garber J, Hay I: AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001, 7:202.
• [2]Haghpanah V, Soliemanpour B, Heshmat R, Mosavi-Jarrahi A, Tavangar S, Malekzadeh R, Larijani B: Endocrine cancer in Iran: based on cancer registry system. Indian J Cancer 2006, 43:80.
• [3]Larijani B, Shirzad M, Mohagheghi M, Haghpanah V, Mosavi-Jarrahi A, Tavangar S, Vassigh A, Hossein-Nezhad A, Bandarian F, Baradar-Jalili R: Epidemiologic analysis of the Tehran cancer institute data system registry (TCIDSR). Asian Pac J Cancer Prev 2004, 5:36-39.
• [4]Glattre E, Haldorsen T: Positive correlation between parity and incidence of thyroid cancer: new evidence based on complete Norwegian birth cohorts. Int J Cancer 1991, 49:831-836.
• [5]Memon A, Darif M, Al-Saleh K, Suresh A: Epidemiology of reproductive and hormonal factors in thyroid cancer: Evidence from a case–control study in the Middle East. Int J Cancer 2002, 97:82-89.
• [6]Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M: Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol Biomarkers Prev 1999, 8:991-997.
• [7]Amoli MM, Yazdani N, Amiri P, Sayahzadeh F, Haghpanah V, Tavangar SM, Amirzargar A, Ghaffari H, Nikbin B, Larijani B: HLA-DR association in papillary thyroid carcinoma. Dis Markers 2010, 28:49-53.
• [8]Maso LD, Vecchia CL, Franceschi S, Preston-Martin S, Ron E, Levi F, Mack W, Mark SD, McTiernan A, Kolonel L: A pooled analysis of thyroid cancer studies. V. Anthropometric factors. Cancer Causes Control 2000, 11:137-144.
• [9]Spitz MR, Sider JG, Katz RL, Pollack ES, Newell GR: Ethnic patterns of thyroid cancer incidence in the United States, 1973–1981. Int J Cancer 1988, 42:549-553.
• [10]Laurberg P, Nøhr S, Pedersen K, Hreidarsson A, Andersen S, Pedersen IB, Knudsen N, Perrild H, Jørgensen T, Ovesen L: Thyroid disorders in mild iodine deficiency. Thyroid 2000, 10:951-963.
• [11]Yazdani N, Sayahpour FA, Haghpanah V, Amiri P, Shahrabi-Farahani M, Moradi M, Mirmiran A, Khorsandi M-T, Larijani B, Mostaan LV: Survivin gene polymorphism association with papillary thyroid carcinoma. Pathol Res Pract 2012, 208:100-103.
• [12]Williams E, Doniach I, Bjarnason O, Michie W: Thyroid cancer in an iodide rich area. A histopathological study. Cancer 1977, 39:215-222.
• [13]Davies L, Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. J Am Med Assoc 2006, 295:2164-2167.
• [14]Castro MR, Gharib H: Thyroid nodules and cancer. When to wait and watch, when to refer. Postgrad Med 2000, 107:113.
• [15]Mortensen J, Woolner LB, Bennett WA: Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab 1955, 15:1270-1280.
• [16]Roth LM: Tumors of the Thyroid Gland. Am J Surg Pathol 1993, 17:1196.
• [17]McNicol A: Functional Endocrine Pathology. Histopathology 1992, 20:92. 92
• [18]Gilliland FD, Hunt WC, Morris DM, Key CR: Prognostic factors for thyroid carcinoma. Cancer 1997, 79:564-573.
• [19]Wartofsky L, Van Nostrand D: Thyroid cancer: a comprehensive guide to clinical management. New Jersey: Humana Pr Inc; 2006.
• [20]Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A: Anaplastic thyroid carcinoma. Cancer 2005, 103:1330-1335.
• [21]Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G, Pierotti MA: Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Investig 1993, 91:1753.
• [22]Demeter J, De Jong S, Lawrence A, Paloyan E: Anaplastic thyroid carcinoma: risk factors and outcome. Surgery 1991, 110:956.
• [23]Zhang Q, Yang C, Guo Z, Zeng Z, Yang A, Lai F: Prognostic factors of medullary thyroid carcinoma. Chin J Otorhinolaryngol Head Neck Surg 2008, 43:939.
• [24]Hyer S, Vini L, Harmer C: Medullary thyroid cancer: multivariate analysis of prognostic factors influencing survival. Eur J Surg Oncol 2000, 26:686-690.
• [25]Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA: Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 1984, 63:319.
• [26]Peto R: Epidemiology, multistage models, and short-term mutagenicity tests. Orig Human Cancer 1977, 4:1403-1428.
• [27]Weinberg RA: Tumor suppressor genes. Science 1991, 254:1138-1146.
• [28]Levine AJ: The p53 tumor-suppressor gene. N Engl J Med 1992, 326:1350-1352.
• [29]Freeman J, Carroll C, Asa S, Ezzat S: Genetic events in the evolution of thyroid cancer. J Otolaryngol 2002, 31:202-206.
• [30]Nakamura T, Yana I, Kobayashi T, Shin E, Karakawa K, Fujita S, Miya A, Mori T, Nishisho I, Takai S: p53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Cancer Sci 1992, 83:1293-1298.
• [31]Zou M, Shi Y, Farid N: p53 mutations in all stages of thyroid carcinomas. J Clin Endocrinol Metab 1993, 77:1054-1058.
• [32]Bos JL: The ras gene family and human carcinogenesis. Mutat Res Rev Genet Toxicol 1988, 195:255-271.
• [33]Barbacid M: Ras genes. Annu Rev Biochem 1987, 56:779-827.
• [34]Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 1989, 49:4682.
• [35]Suárez HG: Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol 1998, 48:531-546.
• [36]Lemoine N, Mayall E, Wyllie F, Williams E, Goyns M, Stringer B, Wynford-Thomas D: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989, 4:159.
• [37]Kim D, McCabe C, Buchanan M, Watkinson J: Oncogenes in thyroid cancer. Clin Otolaryngol Allied Sci 2003, 28:386-395.
• [38]Shi Y, Zou M, Schmidt H, Juhasz F, Stensky V, Robb D, Farid NR: High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area. Cancer Res 1991, 51:2690.
• [39]Wright P, Lemoine N, Mayall E, Wyllie F, Hughes D, Williams E, Wynford-Thomas D: Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer 1989, 60:576.
• [40]Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, Sekikawa K, Hagiwara K, Takenoshita S: BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003, 22:6455-6457.
• [41]Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G: Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 2003, 21:3226-3235.
• [42]Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X: Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005, 103:2261-2268.
• [43]Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI: Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008, 93:278-284.
• [44]Hou P, Liu D, Shan Y, Hu S, Studeman K, Condouris S, Wang Y, Trink A, El-Naggar AK, Tallini G: Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res 2007, 13:1161-1170.
• [45]Learoyd DL, Marsh DJ, Richardson AL, Twigg SM, Delbridge L, Robinson BG: Genetic testing for familial cancer: consequences of RET proto-oncogene mutation analysis in multiple endocrine neoplasia, type 2. Arch Surg 1997, 132:1022.
• [46]Fusco A, Grieco M, Santoro M, Berlingieri M, Pilotti S, Pierotti M, Della Porta G, Vecchio G: A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature 1987, 328:170-172.
• [47]Hansford JR, Mulligan LM: Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis. J Med Genet 2000, 37:817-827.
• [48]Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A: RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995, 11:1207.
• [49]Grieco M, Santoro M, Berlingieri MT, Melillo RM, Donghi R, Bongarzone I, Pierotti MA, Della Ports G, Fusco A, Vecchiot G: PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
• [50]Lips C, Landsvater RM, Hoppener J, Geerdink RA, Blijham G, van Veen JMJS, van Gils A, de Wit MJ, Zewald RA, Berends M: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828-835.
• [51]Ishizaka Y, Shima H, Sugimura T, Nagao M: Detection of phosphorylated retTPC oncogene product in cytoplasm. Oncogene 1992, 7:1441.
• [52]Heshmati HM, Gharib H, Khosla S, Abu-Lebdeh HS, Lindor NM, Thibodeau SN: Genetic testing in medullary thyroid carcinoma syndromes: mutation types and clinical significance. In Mayo Clinic; 27-30 May 1997. Rochester: Elsevier; 1997:430-436.
• [53]Marsh DJ, Robinson BG, Andrew S, Richardson AL, Pojer R, Schnitzler M, Mulligan LM, Hyland VJ: A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families. Genomics 1994, 23:477-479.
• [54]Höppner W, Ritter MM: A duplication of 12 bp in the critical cysteine rich domain of the RET proto-oncogene results in a distinct phenotype of multiple endocrine neoplasia type 2A. Hum Mol Genet 1997, 6:587. 587
• [55]Höppner W, Dralle H, Brabant G: Duplication of 9 base pairs in the critical cysteine-rich domain of the RET proto-oncogene causes multiple endocrine neoplasia type 2A. Hum Mutat 1998, 11:S128-S130.
• [56]Mulligan LM, Marsh D, Robinson B, Schuffenecker I, Zedenius J, Lips C, Gagel R, Takai SI, Noll W, Fink M: Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995, 238:343-346.
• [57]Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HKP, Lips CJM, Nishisho I, Takai SI: The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. J Am Med Assoc 1996, 276:1575-1579.
• [58]Gimm O, Marsh DJ, Andrew SD, Frilling A, Dahia PLM, Mulligan LM, Zajac JD, Robinson BG, Eng C: Germline dinucleotide mutation in codon 883 of the RETproto-oncogene in multiple endocrine neoplasia Type 2B without codon 918 mutation. J Clin Endocrinol Metab 1997, 82:3902-3904.
• [59]Wajjwalku W, Nakamura S, Hasegawa Y, Miyazaki K, Satoh Y, Funahashi H, Matsuyama M, Takahashi M: Low Frequency of Rearrangements of the ret and trk Proto-oncogenes in Japanese Thyroid Papillary Carcinomas. Cancer Sci 1992, 83:671-675.
• [60]Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE: PAX8-PPAR [gamma] rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol 2002, 26:1016.
• [61]Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR: The ins and outs of Raf kinases. Trends Biochem Sci 1994, 19:474.
• [62]Lang J, Boxer M, MacKie R: Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat 2003, 21:327-330.
• [63]Avruch J, Khokhlatchev A, Kyriakis JM, Luo Z, Tzivion G, Vavvas D, Zhang XF: Ras activation of the Raf kinase. Recent Prog Horm Res 2001, 56:127-156.
• [64]Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer. Cancer Res 2003, 63:1454.
• [65]Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH: BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol 2004, 17:1359-1363.
• [66]Soares P, Trovisco V, Rocha AS, Feijao T, Rebocho AP, Fonseca E, Vieira de Castro I, Cameselle-Teijeiro J, Cardoso-Oliveira M, Sobrinho-Simoes M: BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch 2004, 444:572-576.
• [67]Takano T, Ito Y, Hirokawa M, Yoshida H, Miyauchi A: BRAFV600E mutation in anaplastic thyroid carcinomas and their accompanying differentiated carcinomas. Br J Cancer 2007, 96:1549-1553.
• [68]Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW, Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003, 95:625-627.
• [69]Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T, Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003, 88:4393-4397.
• [70]Webb CP, Van Aelst L, Wigler MH, Vande Woude GF: Signaling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci 1998, 95:8773.
• [71]Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE: Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934. 934
• [72]Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, Máximo V, Botelho T, Seruca R, Sobrinho-Simões M: BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003, 22:4578-4580.
• [73]Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA: PAX8-PPARgamma 1 fusion in oncogene human thyroid carcinoma. Sci Signal 2000, 289:1357.
• [74]Wu Y, Guo SW: Peroxisome proliferator-activated receptor-gamma and retinoid X receptor agonists synergistically suppress proliferation of immortalized endometrial stromal cells. Fertil Steril 2009, 91:2142-2147.
• [75]Ros P, Rossi DL, Acebrón A, Santisteban P: Thyroid-specific gene expression in the multi-step process of thyroid carcinogenesis. Biochimie 1999, 81:389-396.
• [76]Giordano TJ, Au AYM, Kuick R, Thomas DG, Rhodes DR, Wilhelm KG, Vinco M, Misek DE, Sanders D, Zhu Z: Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin Cancer Res 2006, 12:1983-1993.
• [77]Kondo T, Ezzat S, Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006, 6:292-306.
• [78]Castro P, Rebocho A, Soares R, Magalhaes J, Roque L, Trovisco V, de Castro IV, Cardoso-de-Oliveira M, Fonseca E, Soares P: PAX8-PPARγ rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:213-220.
• [79]Bullock MD, Sayan AE, Packham GK, Mirnezami AH: MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 2012, 104:3-12.
• [80]De Arcangelis A, Georges-Labouesse E, Adams JC: Expression of fascin-1 the gene encoding the actin-bundling protein fascin-1, during mouse embryogenesis. Gene Expr Patterns 2004, 4:637-643.
• [81]Tubb BE, Bardien-Kruger S, Kashork CD, Shaffer LG, Ramagli LS, Xu J, Siciliano MJ, Bryan J: Characterization of Human Retinal Fascin Gene (< i > FSCN2) at 17q25: Close Physical Linkage of Fascin and Cytoplasmic Actin Genes. Genomics 2000, 65:146-156.
• [82]Tubb B, Mulholland DJ, Vogl W, Lan ZJ, Niederberger C, Cooney A, Bryan J: Testis fascin (FSCN3): a novel paralog of the actin-bundling protein fascin expressed specifically in the elongate spermatid head. Exp Cell Res 2002, 275:92-109.
• [83]Adams JC: Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004, 16:590-596.
• [84]Kureishy N, Sapountzi V, Prag S, Anilkumar N, Adams JC: Fascins, and their roles in cell structure and function. Bioessays 2002, 24:350-361.
• [85]Chen G, Zhang FR, Ren J, Tao LH, Shen ZY, Lv Z, Yu SJ, Dong BF, Xu LY, Li EM: Expression of fascin in thyroid neoplasms: a novel diagnostic marker. J Cancer Res Clin Oncol 2008, 134:947-951.
• [86]Hashimoto Y, Loftis DW, Adams JC: Fascin-1 promoter activity is regulated by CREB and the aryl hydrocarbon receptor in human carcinoma cells. PLoS One 2009, 4:e5130.